Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang, Bowen Chen, Yanyu Wang, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 709-719
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Nan Zhang, Yang Xu, Mingjian Piao, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
Xu Yang, Baofeng Lian, Nan Zhang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
Shunzhen Zheng, Siew Wee Chan, Fei Liu, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1582-1582
Open Access | Times Cited: 12
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
Xu Li, Jinzhang Chen, Chang Liu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
Lingfeng Diao, Chendong Wang, Ran You, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 4, pp. 746-753
Closed Access | Times Cited: 10
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Rafał Becht, Kajetan Kiełbowski, Michał Wasilewicz
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1456-1456
Open Access | Times Cited: 8
Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis
Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, et al.
Hypertension Research (2025)
Open Access | Times Cited: 1
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein‐1 inhibitors: A promising treatment approach for high‐burden hepatocellular carcinoma
Shumin Fu, Yongkang Xu, Mao Ye, et al.
Cancer Medicine (2024) Vol. 13, Iss. 9
Open Access | Times Cited: 5
Advancements in immunotherapy for hepatocellular carcinoma
S. Ascari, Rusi Chen, Caterina Vivaldi, et al.
Expert Review of Anticancer Therapy (2025) Vol. 25, Iss. 2, pp. 151-165
Closed Access
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Dengyong Zhang, Yan Zhu, Zhengchao Shen, et al.
Seminars in Cancer Biology (2025) Vol. 111, pp. 60-75
Closed Access
Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer
Xin Wei, Weihua Cao, Shiyu Wang, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2623-2643
Open Access
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy
Jingzhong Ouyang, Yi Yang, Yanzhao Zhou, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1519-1531
Closed Access | Times Cited: 12
Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma
Beichuan Pang, Bangyou Zuo, Liang Huang, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112492-112492
Closed Access | Times Cited: 4
Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy
Xizhong Shen, Wei Yan, Erlei Zhang, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy
Yi Yang, Lu Li, Ying Xü, et al.
La radiologia medica (2024) Vol. 129, Iss. 2, pp. 188-201
Closed Access | Times Cited: 3
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
Jiashuo Chao, Shanshan Wang, Hao Wang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 11, pp. 3717-3726
Open Access | Times Cited: 8
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
Jingzhong Ouyang, Zhengzheng Wang, Kun Yuan, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1465-1477
Open Access | Times Cited: 7
Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
Jiaming Shen, Xia Wang, Guangde Yang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 207-217
Open Access | Times Cited: 2
Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study
Ying Xiao, Keren Li, Ying Zhao, et al.
BMC Surgery (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Yu-Chun Hsu, Po‐Ting Lin, Wei Teng, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3458-3458
Open Access | Times Cited: 2
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Rui Han, Yuqian Wang, Lingeng Lu
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 59-59
Open Access | Times Cited: 6
Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study
Qi-mei Li, Qingcan Sun, Yan Jian, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 5
The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
Liqiu Kou, Xiaolu Xie, Xiu Chen, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 12, pp. 3953-3969
Open Access | Times Cited: 4
Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors
Ning Cong, Jun Jia, Xinmu Zhang, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 6, pp. 882-897
Open Access | Times Cited: 4
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Hao Li, Jiacheng Wang, Guokun Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top